Eric K Rowinsky

Eric K Rowinsky

UNVERIFIED PROFILE

Are you Eric K Rowinsky?   Register this Author

Register author
Eric K Rowinsky

Eric K Rowinsky

Publications by authors named "Eric K Rowinsky"

Are you Eric K Rowinsky?   Register this Author

100Publications

3859Reads

42Profile Views

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.

Haematologica 2015 Feb 7;100(2):223-30. Epub 2014 Nov 7.

INSERM UMR1098, F25020 Besançon Cedex, France Université de Bourgogne Franche-Comté, SFR FED4234, F25000 Besançon Cedex, France EFS Bourgogne Franche-Comté, F25020 Besançon Cedex, France LabEX LipSTIC, ANR-11-LABX-0021, F25020 Besançon Cedex, France

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2014.111740DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803130PMC
February 2015

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.

Invest New Drugs 2012 Aug 1;30(4):1597-606. Epub 2011 Jun 1.

Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10637-011-9691
Web Search
http://link.springer.com/10.1007/s10637-011-9691-8
Publisher Site
http://dx.doi.org/10.1007/s10637-011-9691-8DOI Listing
August 2012

A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).

Cancer Chemother Pharmacol 2012 Mar 6;69(3):825-34. Epub 2011 Nov 6.

Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center, San Antonio, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-011-1770-1DOI Listing
March 2012

The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.

Cancer Chemother Pharmacol 2012 Feb 6;69(2):563-71. Epub 2011 Nov 6.

Division of Oncology, Department of Medicine, Stanford University and Stanford Cancer Institute, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-011-1772-zDOI Listing
February 2012

Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancers.

Curr Drug Targets 2011 Dec;12(14):2016-33

Department of Clinical Research and Regulatory Affairs, ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, Bridgewater, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138945011798829401DOI Listing
December 2011

Targeting the target of rapamycin (TOR): looking to mother nature.

Authors:
Eric K Rowinsky

Target Oncol 2011 Mar 27;6(1):1-4. Epub 2011 Apr 27.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-011-0180-yDOI Listing
March 2011

Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients.

Clin Cancer Res 2010 Nov 8;16(22):5591-602. Epub 2010 Oct 8.

Division of Medical Oncology University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-2092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2982939PMC
November 2010

Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.

Clin Cancer Res 2010 May 20;16(9):2656-65. Epub 2010 Apr 20.

Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-0062DOI Listing
May 2010

Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10.

Cancer 2010 Feb;116(4 Suppl):1013-7

ImClone Systems Corporation, 33 ImClone Drive, Branchburg, NJ 08876, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.24787DOI Listing
February 2010

Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.

J Clin Oncol 2007 Oct;25(30):4707-13

Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.11.2938DOI Listing
October 2007

Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy.

Clin Cancer Res 2007 Sep;13(18 Pt 2):5544s-5548s

Clinical Affairs Department, ImClone Systems, Inc., Branchburg, New Jersey 08876, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-1107DOI Listing
September 2007

IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.

Clin Cancer Res 2007 Sep;13(18 Pt 2):5549s-5555s

Department of Clinical Research and Regulatory Affairs, ImClone Systems Incorporated, Branchburg, New Jersey 08876, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-1109DOI Listing
September 2007

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas.

Invest New Drugs 2007 Aug 20;25(4):359-67. Epub 2007 Jan 20.

Cross Cancer Institute, 11560 University Avenue, Edmonton, AB T6G 1Z2, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-006-9031-6DOI Listing
August 2007

Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.

Clin Cancer Res 2007 Jun;13(11):3293-301

Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-2496DOI Listing
June 2007

A remedy for biomarker addiction: back to rational anticancer drug development.

Nat Clin Pract Oncol 2007 May;4(5):264-5

ImClone Systems Incorporated, Branchburg, NJ 08876, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncponc0811DOI Listing
May 2007

A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.

Clin Cancer Res 2007 Jan;13(2 Pt 1):532-9

Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-1606DOI Listing
January 2007

Novel agents that target tublin and related elements.

Semin Oncol 2006 Aug;33(4):421-35

ImClone Systems Inc, Branchburg, NJ 08876, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2006.04.006DOI Listing
August 2006

Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors.

Authors:
Eric K Rowinsky

J Clin Oncol 2006 Jul 12;24(19):2981-4. Epub 2006 Jun 12.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.05.9808DOI Listing
July 2006

Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.

Clin Cancer Res 2006 Apr;12(7 Pt 1):2158-65

Department of Oncology, Johns Hopkins University and Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-2249DOI Listing
April 2006

Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.

Clin Cancer Res 2005 Dec;11(24 Pt 1):8728-36

Institute for Drug Development, Cancer Therapy and Research Center, and Department of Pharmacology, University of Texas Health Science Center at San Antonio 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-1572DOI Listing
December 2005

Erosion of the principal investigator role in a climate of industry dominance.

Authors:
Eric K Rowinsky

Eur J Cancer 2005 Oct;41(15):2206-9

University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2005.07.010DOI Listing
October 2005

Raf: a strategic target for therapeutic development against cancer.

J Clin Oncol 2005 Sep;23(27):6771-90

University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.08.036DOI Listing
September 2005

Clinical experience with monoclonal antibodies to epidermal growth factor receptor.

Curr Oncol Rep 2005 Mar;7(2):96-103

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, 7979 Wurzbach Road, 4th Floor, Zeller Building, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-005-0034-9DOI Listing
March 2005

Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor.

Curr Oncol Rep 2005 Mar;7(2):123-8

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, 7979 Wurzbach Road, 4th Floor, Zeller Building, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-005-0038-5DOI Listing
March 2005

Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs.

Clin Lung Cancer 2004 Dec;6 Suppl 1:S35-42

Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center at San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/clc.2004.s.013DOI Listing
December 2004

Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study.

Clin Cancer Res 2004 Nov;10(21):7112-20

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-1187DOI Listing
November 2004

Targeting the molecular target of rapamycin (mTOR).

Authors:
Eric K Rowinsky

Curr Opin Oncol 2004 Nov;16(6):564-75

Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach Road, 4th Floor Zeller Building, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.cco.0000143964.74936.d1DOI Listing
November 2004

A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.

Clin Cancer Res 2004 Oct;10(19):6512-21

Institute for Drug Development, Cancer Therapy and Research Center and University Health Science Center at San Antonio, San Antonio, Texas 78229, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-04-0804DOI Listing
October 2004

Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.

Clin Cancer Res 2004 Aug;10(15):4913-21

Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-0469DOI Listing
August 2004

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.

J Clin Oncol 2004 Aug;22(16):3238-47

Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, 111 E 210th St, Bronx, NY 10467, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2004.11.057DOI Listing
August 2004

Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer.

Clin Colorectal Cancer 2004 Jul;4(2):107-23

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, 4th floor Zeller Building, 7979 Wurzbach Road, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/ccc.2004.n.014DOI Listing
July 2004

Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies.

Authors:
Eric K Rowinsky

Clin Cancer Res 2004 Jun;10(12 Pt 2):4220s-4226s

Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-040013DOI Listing
June 2004

Crossing the cancer cell membrane to improve clinical outcomes.

Authors:
Eric K Rowinsky

Oncologist 2003 ;8 Suppl 3:1-4

Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.8-suppl_3-1DOI Listing
May 2004

Signal events: Cell signal transduction and its inhibition in cancer.

Authors:
Eric K Rowinsky

Oncologist 2003 ;8 Suppl 3:5-17

Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.8-suppl_3-5DOI Listing
May 2004

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors.

Authors:
Eric K Rowinsky

Annu Rev Med 2004 ;55:433-57

Institute for Drug Development of the Cancer Therapy and Research Foundation, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev.med.55.091902.104433DOI Listing
May 2004

Acute retinal toxicity from the novel anti-tumor agent, Irofulven.

Doc Ophthalmol 2004 May;108(3):249-51

Department of Ophthalmology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10633-004-4085-2DOI Listing
May 2004

A widening prospect: Imatinib and novel applications of targeted therapy.

Authors:
Eric K Rowinsky

Semin Oncol 2004 Apr;31(2 Suppl 6):1-3

Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2004.03.033DOI Listing
April 2004

Novel anticancer agents in clinical development.

Cancer Biol Ther 2003 Jul-Aug;2(4 Suppl 1):S5-15

Mayo Clinic and Foundation; Rochester, Minnesota 55905, USA.

View Article

Download full-text PDF

Source
February 2004

The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.

Cancer Biol Ther 2003 Jul-Aug;2(4 Suppl 1):S169-77

Institute for Drug Development; Cancer Therapy and Research Center; San Antonio, Texas 78229, USA.

View Article

Download full-text PDF

Source
February 2004

Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.

Semin Oncol 2003 Oct;30(5 Suppl 16):79-92

Institute for Drug Development, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2003.08.010DOI Listing
October 2003

Dose-intense paclitaxel: deja vu all over again?

J Clin Oncol 2003 Aug 13;21(15):2810-4. Epub 2003 Jun 13.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2003.05.099DOI Listing
August 2003

The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum.

Invest New Drugs 2003 Aug;21(3):269-79

Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/a:1025456224751DOI Listing
August 2003

A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.

Clin Cancer Res 2003 Jul;9(7):2465-71

Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA.

View Article

Download full-text PDF

Source
July 2003

Mammalian target of rapamycin: a new molecular target for breast cancer.

Clin Breast Cancer 2003 Jun;4(2):126-37

Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/cbc.2003.n.018DOI Listing
June 2003